Class-Specific Adverse Events of Patients Treated with Small Interfering RNA&#160;Therapeutics: A Disproportionality Analysis of the United States Food and Drug Administration Adverse Event Reporting System Database Based on the MY FAERS Platform.

Oxlumo (lumasiran) - Alnylam

Onpattro (patisiran) - Alnylam, Sanofi

Leqvio (inclisiran) - Novartis

Givlaari (givosiran) - Alnylam

Amvuttra (vutrisiran) - Alnylam

http://www.ncbi.nlm.nih.gov/pubmed/41274662

Dandan Li; Lin Zhang; Xiaozhen Wang; Xingang Li; Yiqi Sun; Ze Li

Nov 23, 2025